<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Tiziana Life Sciences plc

    Tiziana Life Sciences plc

    Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biot...

    Tiziana Life Sciences is a dual-listed (NASDAQ:...

    Filing Type:    PU
    Seelos Therapeutics, Inc.

    Seelos Therapeutics, Inc.

    Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a responsibly-driven company focused o...

    Seelos Therapeutics, Inc. (Nasdaq: SEEL) is a r...

    Filing Type:    PU
    Anixa Biosciences, Inc.

    Anixa Biosciences, Inc.

    Anixa is focused on harnessing the body’s immune system in the fight against can...

    Anixa is focused on harnessing the body’s imm...

    Filing Type:    PU
    iRadimed Corporation

    iRadimed Corporation

    IRADIMED CORPORATION is a leader in the development of innovative magnetic resonan...

    IRADIMED CORPORATION is a leader in the develop...

    Filing Type:    PU
    Chembio Diagnostics, Inc.

    Chembio Diagnostics, Inc.

    Chembio is a leading point-of-care diagnostics company focused on detecting and di...

    Chembio is a leading point-of-care diagnostics ...

    Filing Type:    PU
    Interpace Diagnostics Group, Inc.

    Interpace Diagnostics Group, Inc.

    Interpace Diagnostics is focused on developing and commercializing molecular diagn...

    Interpace Diagnostics is focused on developing ...

    Filing Type:    PU
    Neoleukin Therapeutics, Inc.

    Neoleukin Therapeutics, Inc.

    Neoleukin is a biopharmaceutical company creating next generation immunotherapies ...

    Neoleukin is a biopharmaceutical company creati...

    Filing Type:    PU
    Merus N.V.

    Merus N.V.

    Merus is a clinical-stage immuno-oncology company developing innovative full-lengt...

    Merus is a clinical-stage immuno-oncology compa...

    Filing Type:    PU
    Jounce Therapeutics, Inc.

    Jounce Therapeutics, Inc.

    Jounce Therapeutics is a clinical stage immunotherapy company dedicated to transfo...

    Jounce Therapeutics is a clinical stage immunot...

    Filing Type:    PU
    Incyte Corporation

    Incyte Corporation

    Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focus...

    Incyte Corporation is a Wilmington, Delaware-ba...

    Filing Type:    PU
    AVEO Pharmaceuticals, Inc.

    AVEO Pharmaceuticals, Inc.

    AVEO Pharmaceuticals, Inc. is a biopharmaceutical company seeking to advance targe...

    AVEO Pharmaceuticals, Inc. is a biopharmaceutic...

    Filing Type:    PU
    ProLung, Inc.

    ProLung, Inc.

    ProLung is a medical technology company specializing in innovative predictive anal...

    ProLung is a medical technology company special...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.